摘要目的探讨p16和nm23-H1在胃癌组织中的表达及其与临床病理因素的关系。方法应用免疫组化标记链霉菌抗生物素-生物素(LSAB)方法，对65例胃癌患者癌组织中p16和nm23-H1蛋白的表达水平进行了检测，并对其结果与患者的临床病理资料进行了相关分析。结果 p16和nm23-H1在胃癌组织中的阳性表达率分别为30.8%、41.5%；在分化好的癌组织，p16的阳性表达率高于分化差的癌组织(P＜0.05)；p16和nm23-H1在无淋巴结转移患者的癌组织中阳性率高于有转移者(P＜0.05、P＜0.01)；在Ⅰ、Ⅱ期患者癌组织中高于Ⅲ期患者癌组织，差异均有显著性意义(P＜0.05、P＜0.01)。p16蛋白表达阳性者3年生存率为45.0%，阴性者为28.9%；nm23-H1蛋白表达阳性者3年生存率为51.9%，阴性者为21.1%，阳性表达者与阴性表达者生存率差异有显著性意义(P＜0.05)。p16与nm23-H1蛋白的表达率呈正相关(r=0.041*!5,P＜0.05)。结论 p16和nm23-H1参与了胃癌的发展过程，并与胃癌的部分生物学行为有关，可作为预测肿瘤转移和评估患者预后的指标。

abstractsObjective　To study the relationship between the expression of p16 and nm23-H1 and clinicopathology in the patients with gastric cancer. 　Methods　p16 and nm23-H1 protein in cancer tissue of 65 patients were observed with labelled streptavidin biotin (LSAB) immunohistochemical method.　Results　The total positive rate of p16 and nm23-H1 was 30.8% and 41.5% respectively in gastric cancer tissues. The positive expression rate of p16 was significantly higher in well-differentiated cancer than in poorly-differentiated cancer (P＜0.05). The positive expression rate of p16 and nm23-H1 was higher in patients with lymph node metastasis than in those without lymph node metastasis(P＜0.05，P＜0.01) and in clinical stage Ⅰ,Ⅱ than in stage Ⅲ (P＜0.05，P＜0.01).The 3-year survival rate was higher in positive cases of p16 or nm23-H1 protein expression (45.0%，51.9%）than in negative ones（28.9%、21.1%）(P＜0.05).There was a significants positive correlation between p16 and nm23-H1 protein expression(r=0.041*!5,P＜0.05).　Conclusions　p16 and nm23-H1 may play a role in the development of gastric cancer and be related to partial biological behavior. Expression of p16 and nm23-H1 may serve as a marker for predicting the cancer metastasis and evaluating the prognosis of gastric cancer patients.